Skip to main content
ADIA
OTC Life Sciences

Adia Nutrition Reports Worsening Losses, Going Concern Warning, and Ineffective Controls; Omits Recent Positive News

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.17
Mkt Cap
--
52W Low
$0.018
52W High
$0.278
52W Position info
860% above low
Off High info
39% below high
Rel. Volume
Market data snapshot near publication time

ADIA has more than doubled off its 52-week low of $0.018.

Summary

Adia Nutrition's Q1 2026 report reveals deepening financial distress, a going concern warning, and ineffective internal controls, while conspicuously omitting recent positive news, raising significant transparency concerns.


Key Events · Legal and Risk Events · ADIA

  • Going Concern Warning Reiterated

    The company continues to express "substantial doubt" about its ability to continue as a going concern due to ongoing losses and cash burn, a concern previously noted in its 10-K filed on March 31, 2026.

  • Worsening Financial Performance

    Net loss increased to $162,525 for the three months ended March 31, 2026, compared to $116,219 in the prior year. Cash used in operations also rose to $55,037 from $31,175, indicating an accelerating cash burn despite revenue growth.

  • Ineffective Internal Controls

    Management concluded that disclosure controls and procedures were not effective as of December 31, 2025, highlighting a critical governance and compliance issue.

  • Increased Related-Party Debt

    The company's line of credit from its CEO increased to $723,656 from $600,000, indicating continued reliance on insider funding to sustain operations.


Analysis · ADIA · Life Sciences

Adia Nutrition's latest quarterly report highlights a deteriorating financial state with increased net losses and cash burn, alongside a reiterated "going concern" warning and ineffective internal controls. Critically, the filing states no material subsequent events occurred through May 13, 2026, directly contradicting recent news releases about a strategic partnership and pivotal clinical study. This raises serious concerns about the company's financial transparency and reporting integrity, especially given its heavy reliance on related-party debt for operations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADIA was trading at $0.17 on OTC in the Life Sciences sector. The 52-week trading range was $0.02 to $0.28. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADIA - Latest Insights

ADIA
Nov 16, 2026, 2:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.128
Real-time Price: $0.111 info
Change: -$0.017 (-13%) info
Market Cap: $10.479M info
ADIA
Oct 19, 2026, 11:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.130
Real-time Price: $0.111 info
Change: -$0.019 (-15%) info
Market Cap: $10.479M info
ADIA
Oct 05, 2026, 7:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.101
Real-time Price: $0.111 info
Change: +$0.0100 (+10%) info
Market Cap: $10.479M info
ADIA
Oct 05, 2026, 4:49 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.101
Real-time Price: $0.111 info
Change: +$0.0100 (+10%) info
Market Cap: $10.479M info
ADIA
Aug 13, 2026, 11:28 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.1195
Real-time Price: $0.111 info
Change: -$0.0085 (-7%) info
Market Cap: $10.479M info